In most cancer types, the lack of correlation between BCAM and PD-L1 expression patterns suggests that BCAM could serve as a therapeutic target for patients less likely to respond to anti-PD-1 and anti-PD-L1 therapies. The gene discussed is PDCD1; the disease is cancer.